CCR2 and ovarian cancer: Inhibition of the CCL2/CCR2 axis using a CCR2 inhibitor significantly increased paclitaxel sensitivity in both in vitro and in vivo models, suggesting that targeting this signaling pathway could be a promising therapeutic strategy to overcome chemoresistance in ovarian cancer.